RV521: Ph I data

Top-line data from a Phase I trial in 48 healthy volunteers showed that single and multiple ascending doses of oral RV521 were well tolerated with no significant treatment-related adverse events reported.

A separate blinded, placebo-controlled, U.K. Phase I trial in 24 healthy volunteers showed that twice-daily 175, 250 and 350 mg doses of oral RV521 for 5 days led to no significant adverse events...